# Pyoderma Gangrenosum

When nothing else fits!



# Glenda Dagger RGON MHPrac in Nursing

Te Whatu Ora Waitemata Educator for District Nursing

Area Coordinator NZ Wound Care Society

Lecturer in PG Wound Management Massey University

Assessor and mentor for Otago Polytech Wound Debridement Course

Disclaimer- In 2023 I received funding from Ainscorp/Fidia Pharma to attend the EWMA conference in Europe.

#### Scenario

Mrs P has been under your care in clinic for treatment of a chronic lower leg wound. She states it began with what she believes was an insect bite as small blisters were visible.

Her main goal of care is to stop the pain the wound is causing.

#### On initial examination the wound was

- Anterior/ medial aspect
- Irregular dusky edges with surrounding erythema
- Approximately 2cm /3cm, shallow
- Moderate haemoserous exudate
- Extremely painful



# **Clinical History**

Mrs P is 70 years old with a history of

- Rheumatoid arthritis
- Hypertension
- Type II diabetes ( HbA1c- 50).
- Mildy obese but has recently lost 10kg
- Constant wound pain is her greatest concern, worse during dressing changes.

#### Medications include:

Dexamethazone -5mg D increased to 20mg during flair ups.

Metformin -10mg D

Quinapril – 10mg D

Panadol 1g-4 x D

Sevredol 10mg – 4 hourly prn

# Investigations

After a month of conservative treatment the wound had not improved and other areas of ulceration had developed around the

initial wound. Investigations included:

 Wound microbiology - light growth of organisms resembling commensal skin flora



• ABPI – 0.9 on both legs

• Tissue biopsy was performed which showed nil abnormalities

# Diagnosis

- It was noted that further ulceration occurred at the **biopsy** site and the wound continued to exacerbate in general becoming more painful- (Pathergy)
- Pathergy is the development or flare of skin lesions after minor trauma, such as a needle prick or biopsy.
- Despite appropriate wound care necrotic areas especially at wound edges increased, accompanied by surrounding erythema.

**Diagnosis - Pyoderma Gangrenosum** 

# Pyoderma Gangrenosum

• Pyoderma gangrenosum (PG) is a rare wound which usually characterized by **highly painful** purulent pustules or deep, rapidly enlarging ulcers with purple, undermined edges.

 It is one of a group of auto-inflammatory disorders known as neutrophilic dermatoses.

They can occur on any part of the body.

 The name pyoderma gangrenosum is historical. The condition is **not** an infection (pyoderma), **nor** does it cause gangrene!





### Diagnosis by Exclusion-when nothing else fits\*

- Often an inflamed dusky ring around the perimeter is observed
- Tissue biopsy will exclude all other causes- infection, malignancy, autoimmune processes, drug- induced vasculitis and vascular disease.
- Histopathology of ulcer edge may show a neutrophilic infiltrate.
- More common in women aged 40-60
- 50% -70% of cases will have an **underlying autoimmune** disorder such as
  - ➤RA (16%)
  - ➤ Inflammatory Bowel disease (64%)
  - ➤ Multiple myeloma/haematological malignancies(11%)
- 15% of PG cases are associated with stoma formation
- Patients may have a positive ANCA (antineutrophil cytoplasmic antibody).

#### <u>Living With Chronic Wounds: Finland – Patient</u>

https://www.youtube.com/watch?v=RIA3W4nafW0



### **Systemic Treatment Options**

Usually for larger ulcers due to pyoderma gangrenosum may include:

- Oral prednisone for several weeks or longer, or intermittent intravenous methylprednisolone for 3–5 days
- <u>Cyclosporine</u>, which is as effective as prednisone and has differing adverse effects and risks
- <u>Biologic agents</u>: There is a growing body of evidence for success with the Tumor necrosis factor (TNF)-alpha inhibitors
   e.g. <u>infliximab</u>, <u>adalimumab</u>, <u>etanercept</u>
- Oral anti-inflammatory antibiotics such as <u>doxycycline or</u> <u>minocycline</u>
- Methotrexate



# **Topical Treatment Options**

- Topical local anaesthesia during dressing changes <u>e.g.lignocaine</u>
- Non irritant <u>anti-microbial cleansers</u> to prevent secondary infection
- Potent topical corticosteroid application as part of dressing regime
- <u>Tacrolimus ointment</u> (calcineurin inhibitors work by blocking calcineurin, a protein in our bodies that helps activate our immune system).
- Intra-lesional steroid injections into the ulcer edge
- Cyclosporin solution

33

### **Wound Treatment Barriers and Solutions**

### **Barriers**

#### Slough and biofilm/infection

- Typically slough will form but any sharp or mechanical debridement, though tempting, can result in pathergy.
- Pathergy, the hallmark of PG means any physical action on the wound with make it worse (remember Mrs P's biopsy).

### **Solutions**

- Dressings to enhance autolytic debridement\_if slough present, and exudate management
  - Hydrocolloids
  - Foam
  - Gelling Fibres
- Hydrofera Blue antimicrobial and anti-inflammatory (M-blue)

Hydrofera"

 Enzymatic slough reduction – Hyal4O Start and Silver Spray (Hyaluronic Acid & collagenase)

Iodosorb can be very painful

### **Wound Treatment Barriers and Solutions-cont**

### **Barriers**

#### **Pain**

 Wound pain is generally severe with these patients limiting cleansing options.

#### Leakages

 Leakages and frequent or traumatic bag changes will exacerbate wound -pathergy





### **Solutions**

- Protection from ongoing irritation and pressure using skin protectant wipes, gels and film dressings or hydrocolloid patches over PG under appliance.
- Silicon based primary dressings to reduce skin trauma
- Adhesive removers
- 2 piece systems to reduce friction and trauma at each bag change and good education around bag changes.
- Topical analgesia as per previous slide

#### **Wound Treatment Barriers and Solutions**

#### **Barriers**

#### PG on limbs with venous ulceration

 Normal compression bandaging if indicated (ABPI) may not be tolerated due to pressure aggravating the wound and pain.

#### **Scarring**

- Cribriform (criss cross) scarring can be obvious at the site of the wound.
- Don't underestimate the traumatic effect of changes in body image consider both stoma formation and scarring.

### Solutions

- Light compression bandaging
- Encourage venous/ lymphatic drainage using limb elevation and ensure diuretic treatments are maintained
- Grafting, and in severe cases, amputation, should be avoided during active disease as further PG can occur at the graft or stump site.
- Skin grafting may be indicated to reduce scarring both for healing and after resolution ??????????

# Support for you and for them

### Support from the multi-disciplinary team is paramount

- Dermatologist
- Gastro
- Dietitian
- Homecare nurses
- Pain Specialists
- Ostomy patient groups

#### Support for the nurse

- Share with MDT and colleagues
- Professional Supervision



#### PG is rare...but

...but have you noticed an increase in patients presenting with PG either around stomas or on lower limbs?

- During COVID-19 infection, primary wound healing processes always prolong and the underlying mechanism for this is unclear
- Multiple authors have hypothesized that exposure to the COVID-19 spike protein antigen via infection or vaccination may trigger an autoimmune response that mediates PG
- ► Low level research at this stage.

### Pyoderma Granulosum-Summary

- PG is an uncommon, extremely painful disorder usually effecting the skin integrity and healing processes of patients with autoimmune associated disease.
- It more commonly effects women aged between 40 and 60.
- Management requires an inter-professional approach.
- Diagnosis is made through the exclusion of other pathology.
- Treatment is dependent on the size of the lesion but is usually a systemic and local approach.
- Early recognition and diagnosis is essential to optimal care.
- The increased incidence after COVID or COVID vaccination is currently a topic for study and debate.
- Help each other.

#### References

- Tippet, A. (2012). Recognizing and Treating Wounds Caused by Pyoderma Gangrenosum. Wound Source <a href="https://www.woundsource.com/blog/recognizing-and-treating-wounds-caused-pyoderma-gangrenosum">https://www.woundsource.com/blog/recognizing-and-treating-wounds-caused-pyoderma-gangrenosum</a>
- Naughton, B. (2020). Weird Wounds Part 1: Pyoderma Gangrenosum. Wound Source https://www.woundsource.com/blog/weird-wounds-part-1-pyoderma-gangrenosum
- Hoven, H. (2020). Peristomal Skin Conditions: Pyoderma Gangrenosum. Wound Source. https://www.woundsource.com/blog/peristomal-skin-conditions-pyoderma-gangrenosum
- Oakley, A.(2015). Pyoderma gangrenosum. Dermnet. https://dermnetnz.org/topics/pyoderma-gangrenosum
- Pompeo M. Q. (2016). Pyoderma Gangrenosum: Recognition and Management. Wounds: a compendium of clinical research and practice, 28(1), 7–13. https://pubmed.ncbi.nlm.nih.gov/26779805/
- https://www.youtube.com/watch?v=WO5NxFIXeXw
- Conwell, P. (2021) Pyoderma Gangrenosum Treatment A Steroid Free Option. Poster presentation. Wound Source <a href="https://www.woundsource.com/poster/wc-hydrofera-pyoderma-gangrenosum-treatment-steroid-free-option">https://www.woundsource.com/poster/wc-hydrofera-pyoderma-gangrenosum-treatment-steroid-free-option</a>
- Zou, H., & Daveluy, S. (2023). Pyoderma gangrenosum after COVID-19 infection and vaccination. Clinics in dermatology, 41(1), 129–131.
  <a href="https://doi.org/10.1016/j.clindermatol.2022.11.003">https://doi.org/10.1016/j.clindermatol.2022.11.003</a>
- Li D, Cao W, Zhou Q, Wu X, Song X, Qin H. COVID-19 and primary wound healing: A new insights and advance. Int Wound J. 2023;20(10):4422-4428. doi:10.1111/iwj.14324